Log In
BCIQ
Print this Print this
 

ALN-HDV

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting the hepatitis delta viral (HDV) genome developed using Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis D virus (HDV)
Indication DetailsTreat hepatitis delta virus (HDV) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today